Epstein Secrets

both the IPR decision and the lower court ruling can be appealed. Amanda Ens EFTA00820342 Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

both the IPR decision and the lower court ruling can be appealed. EFTA00820351 Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 Phone: Mobile: The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop